This Analyst Sees Nearly 500% Upside in Avanir Pharmaceuticals (AVNR)

December 15, 2011 2:47 PM EST
Get Alerts AVNR Hot Sheet
Price: $16.96 --0%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AVNR Now!
Join SI Premium – FREE
Shares of Avanir Pharmaceuticals (NASDAQ: AVNR) are down 16 percent since reporting fourth quarter numbers after the close on Monday, but according to one analyst shares should be higher... much higher.

In a note dated 12/13, Summer Street lifted its price target on the maker of Nuedexta from $10 to $11 while reiterating their Buy rating.

The firm noted 10,210 prescriptions were written for Nuedexta during the fourth quarter, a 99% increase over the third quarter. The treatment for pseudobulbar affect (PBA) and neuropathic pain (NP) is growing at a strong 3-4% week-over-week average pace in the fiscal first quarter of 2012. They see roughly 4,800 prescriptions in November. This would be up from 4,100 in October and just 2,746 in July.

The firm estimates that an annualized 1,200 total weekly prescriptions would cover the fixed expenses of the company's specialty retail and institutional care sales force.

The company also continues to work with payers to ensure reimbursement. "Beginning January 1, 2012, AVNR has agreements with three of the top five payers that manage prescription plans," the firm notes. The company expects 35% of patients will have unrestricted access to Nuedexta.

In the EU, Avanir's Marketing Authorization Application (MAA) filing was accepted on November 17 and decision is expected in June 2012 at the earliest.

The firm's $11 price target is based on a 25x multiple of their FY:15 EPS of $0.77/share discounted at 20%.

With shares of Avanir trading at $1.90 per share, the $11 price target represents 480% upside.

For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment